|Date||27 January 2021 – present |
(mass vaccination started on 7 Feb 2021)
|Target||Immunization against COVID-19|
|Organized by|| DGHS |
|Participants||59,153,066 people have registered for vaccination and a total of 72,028,220 doses of vaccine have been administered so far of which |
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
The Oxford–AstraZeneca vaccine was the only COVID-19 vaccine authorized for emergency use from January to April 2021. Bangladesh ordered vaccines produced by Serum Institute of India, however it delivered less than half of the doses as agreed to Bangladesh.After the vaccine shortage due to this, Bangladesh approved the Russian Sputnik V and Chinese Sinopharm BIBP vaccines for emergency use in late April 2021. Bangladesh has also authorized the emergency of Pfizer–BioNTech COVID-19 vaccine and to be distributed as part of COVAX. It was reported that the Bangladesh government planned to give permission to Bangladeshi made Bangavax developed by Globe Biotech Ltd. to conduct the first clinical trial that got listed in the 'Draft landscape and tracker of Covid-19 candidate vaccines' by the World Health Organization (WHO). However fate of the Bangavax is still uncertain due to an unknown reason. As of October 2021, Bangladesh has fully approved 7 COVID-19 vaccine.
On 21 June 2020, China invited Bangladesh to get priority access to a COVID-19 vaccine once it was successfully developed.In July 2020, Sinovac Biotech was given approval by the Bangladesh Medical Research Council to begin a Phase III trial of CoronaVac at the International Centre for Diarrhoeal Disease Research, Bangladesh. However, Bangladesh later decided to cancel the trial of the vaccine after Sinovac asked to co-fund the domestic trials, which would have cost roughly $7 million.
On 2 July 2020, a Bangladeshi private pharmaceutical company named Globe Biotech Limited claimed to be the first company from Bangladesh to have a COVID-19 vaccine under development.The lone Bangladeshi company actually developed three COVID-19 vaccine candidates, all with different technologies. The company named the mRNA based vaccin as Bangavax, which was initially called Bancovid. Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax.
On 5 November 2020, a tripartite agreement was signed between the government of Bangladesh, the Serum Institute of India, and Beximco Pharma of Bangladesh. Under the agreement, Bangladesh ordered 30 million doses of Oxford–AstraZeneca vaccine from Serum through Beximco costing $4 per shot. The Bangladesh government paid in advance for 15 million doses.
However, Serum supplied only 7 million doses in the first two months of 2021 and 3.2 million doses of Oxford–AstraZeneca vaccine were supplied by Government of India as a gift.Bangladesh was supposed to receive 5 million doses per month but did not receive any shipments in March and April. As a result, the rollout of vaccinations was disrupted. Bangladesh then looked to alternative vaccine sources because India had halted exports. Bangladesh suspended the first dosing of the Oxford-AstraZeneca vaccine from 26 April 2021 due to the supply crunch.
The situation became complicated when the second dose for 1.3 million citizens was uncertain as India halted exports to Bangladesh.The country was worried about whether they would get the second dose at the right time or whether another vaccine would need to be given as a second dose instead. According to experts it would not be wise to inoculate one person with different brands of vaccines. Health experts and the opposition party criticized the government for only relying on India for vaccines instead of multiple sources. In addition, several citizens of Bangladesh have expressed doubts about the vaccine's effectiveness and safety.
On 27 April 2021, Bangladesh's drug regulator authorized the emergency use of Russia's Sputnik V vaccine.Russia had proposed to produce their vaccine in Bangladesh with joint collaboration with a local pharmaceutical company. Bangladesh has already given policy approval in this regard.
On 29 April 2021, Bangladesh's drug regulator authorized the emergency use of China's Sinopharm BIBP vaccine.Bangladesh ordered 15 million doses of the Sinopharm BIBP vaccine and received 500,000 doses as a gift. Bangladesh health department has begun administering the vaccine to 1,000 medical students in the beginning to observe its effect and safety. According to Mahbubur Rahman, DGDA Director General, “Mass inoculation will start after the observation period.” It is reported that Bangladesh also wants to produce this vaccine locally. It is reported that Bangladesh was interested in producing CoronaVac in addition to the manufacturing being done in China. China has announced that they will send 600,000 doses of the Sinopharm BIBP vaccine to Bangladesh as a gift.
On 27 May 2021, Directorate General of Drug Administration authorized the emergency use of Pfizer–BioNTech COVID-19 vaccine.COVAX is sending 106,000 doses of Pfizer's Covid vaccine on June 2.
On 6 June 2021, DGDA authorized the emergency use of CoronaVac.
As of 11 June 2021, Bangladesh has received commitment to acquire 1.8 million AstraZeneca vaccines under the Covax programme as shared by Foreign Minister AK Abdul Momen.Earlier. it had been projected that there might have been a shortage of vaccines for some 1.5 million people who awaited the second dosage, due to projected shortage of AstraZeneca vaccines in Bangladesh induced by the export restrictions on the vaccine imposed by India.
On 13 June 2021, China sent 600,000 doses of the Sinopharm BIBP vaccine as a gift.
On 15 June 2021, Directorate General of Drug Administration authorized the emergency use of the Janssen COVID-19 vaccine.DGHS is the local distributor of the vaccine.
On 25 June 2021, Health Minister Zahid Maleque announced Bangladesh would get 2.5 million doses of the Moderna COVID-19 vaccine within the next ten days from COVAX facilities.For this, Bangladesh approved the Moderna COVID-19 vaccine on 29 June 2021.
Bangladesh received 2.5 million Moderna COVID-19 vaccine on 2 July under COVAX from USA and 2 million doses of the Sinopharm BIBP vaccine on 3 July 2021.
Bangladesh received 3 million Moderna COVID-19 vaccine on 19 July under COVAX from USA.
Japan has sent 245,000 Astra-Zeneca vaccines on 24 July. They agree to send total 2.9 million Astra-Zeneca vaccines.
Japan has sent 781,000 doses on 31 Julyand 616,780 doses of Astra-Zeneca vaccines on 2 July 2021.
On 11 August, Bangladesh received 1.77 million doses of the Sinopharm BIBP vaccine under COVAX from China.
On 12 August, Bangladesh decide to procure six crore more doses of the Sinopharm BIBP vaccine from China.
On 13 August 2021, China has sent 1 million doses of the Sinopharm BIBP vaccine to Bangladesh as a gift.
On 16 August,a deal signed between the Bangladesh government, China's Sinopharm and Bangladesh's Incepta Vaccines Ltd for bottling, labelling and dispensing China's Sinopharm BIBP vaccine.
On 21 August 2021, Japan has sent 7.81 lakh doses of Astra-Zeneca vaccines under COVAX.
On 28 August 2021, Japan has sent 6.34 lakh doses of Astra-Zeneca vaccines under COVAX.
On 31 August 2021, 5.5 miilion doses of the Sinopharm BIBP vaccine arrived from China.
On 1 September 2021, 1 million doses of Pfizer–BioNTech COVID-19 vaccine arrived from United States under COVAX.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021, focusing initially on a pilot program of 500 health workers,while mass vaccination started on 7 February 2021. It was planned that 6 million doses would be administered in the first month, and a further 5 million the following month. An online registration portal was launched where citizens registered using their NID number. Initially, registration was open to those aged 55 and above, but due to lower than expected take-up, this was promptly lowered to ages 40 and above. On 5 July 2021, after the vaccination programme had re-opened, DGHS announced the registration age would be lowered to 35 years and then 30 years on 19 July.
University vaccination or Univac was launched to vaccinate university students.Since the vaccination minimum age was reduced to 18, but many did not have NID to register at the main government vaccine website(https://surokkha.gov.bd) another website(https://univac.ugc.gov.bd) was launched to allow university students with birth certificates to register for the vaccine. On November 2nd, the campaign to vaccinate 12-17 year olds in school started. They had to register through their schools to be vaccinated.
|Oxford-AstraZeneca||Yes||Yes||39 million||8 million||8.7 million||16.7 million||14.2 million|
|Sputnik V||Yes||No||40 million|
|Sinopharm BIBP||Yes||Yes||75 million||50 million||5.5 million||55.5 million||51.7 million|
|Pfizer–BioNTech||Yes||Yes||13.1 million||9.6 million||9.6 million||9.6 million||875,000|
|CoronaVac||Yes||Yes||60 million||1 million||1 million||1 million|
|Moderna||Yes||Yes||7.3 million||5.5 million||5.5 million||5.5 million||5.25 million|
Vaccine diplomacy, a form of medical diplomacy, is the use of vaccines to improve a country's diplomatic relationship and influence of other countries. Meanwhile, vaccine diplomacy also "means a set of diplomatic measures taken to ensure access to the best practices in the development of potential vaccines, to enhance bilateral and/or multilateral cooperation between countries in conducting joint R&D, and, in the case of the announcement of production, to ensure the signing of a contract for the purchase of the vaccine at the shortest term." Although primary discussed in the context of the supply of COVID-19 vaccines, it also played a part in the distribution of the smallpox vaccine.
COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO). It is one of the three pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well logistics, country readiness and in-country delivery.
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.
The COVID-19 vaccination program in the Philippines is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Canada is an ongoing, intergovernmental effort coordinated between the bodies responsible in the Government of Canada to acquire and distribute vaccines to individual provincial and territorial governments who in turn administer authorized COVID-19 vaccines during the COVID-19 pandemic in Canada. Provinces have worked with local municipal governments, hospital systems, family doctors and independently owned pharmacies to aid in part, or in full with vaccination rollout. The vaccination effort in full is the largest such immunization effort in the nation's history. The vaccination effort began December 14, 2020 and is currently ongoing.
The COVID-19 vaccination in Morocco is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Vaccine Maitri is a humanitarian initiative undertaken by the Indian government to provide COVID-19 vaccines to countries around the world. The government started providing vaccines from 20 January 2021. As of 9 May 2021, India had delivered around 66.3 million doses of vaccines to 95 countries. Of these, 10.7 million doses were gifted to 47 countries by the Government of India. The remaining 54 million were supplied by the Serum Institute of India under its commercial and COVAX obligations. In late March 2021, the Government of India temporarily froze exports of the Covishield, citing India's own COVID crisis and the domestic need for these vaccines. The Health Minister of India, Mr. Mansukh Mandaviya announced in September that India will resume the export of vaccines from October to the rest of the world.
COVID-19 vaccination programs have begun in many countries and territories in Africa. As of 5 July 2021, vaccination campaigns had started in 51 African countries with 36.5 million people receiving at least one dose.
Bhutan has promised a free COVID-19 vaccination to all of its citizens, both inside and outside the country. It started mass vaccinations on 27 March 2021.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks fifth in the world and second in Asia.
Nepal began administration of COVID-19 vaccines on 27 January 2021. 1 million Oxford-Astrazeneca vaccines were provided by India as a grant while Nepal brought 2 million doses from Serum Institute of India (SII) and was one of the first to receive COVID-19 vaccines. The delivery of the first 1 million doses arrived on 21 February. In March, India's decision to ban exports of vaccines created uncertainty over whether Nepal would be able to continue its vaccinations. By April, SII had only provided half of the 2 million doses for which Nepal had paid in full. A spokesperson for the Indian Ministry of External Affairs rejected the notion of an export ban and said “We will export vaccines taking into account the domestic demand.” By late July, there was still uncertainty in Nepal over when SII would deliver the vaccines that were purchased, although Prime Minister Narendra Modi said India would "resume the supply of vaccines soon."
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 18 March 2021, vaccinations commenced on 22 March 2021, and will continue throughout the year with the goal of vaccinating 70% of the population by late October 2021.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.